The effects of normal aging and ApoE genotype on the levels of CSF biomarkers for Alzheimer's disease

Neurobiology of Aging

Volumn 30, Issue 5, 2009, Pages 672-681

  Glodzik Sobanska, Lidia ^a   Pirraglia, Elizabeth ^a   Brys, Miroslaw ^a   de Santi, Susan ^a   Mosconi, Lisa ^a   Rich, Kenneth E ^a   Switalski, Remigiusz ^a   Louis, Leslie Saint ^a   Sadowski, Martin J ^a   Martiniuk, Frank ^a   Mehta, Pankaj ^b   Pratico, Domenico ^c   Zinkowski, Raymond P ^d   Blennow, Kaj ^e   de Leon, Mony J ^a,f  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NEW YORK STATE INSTITUTE FOR BASIC RESEARCH IN DEVELOPMENTAL DISABILITIES   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d Applied NeuroSolutions Inc   (United States)

^e SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^f NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

Author keywords

Alzheimer's disease; Biomarkers; Cerebrospinal fluid; Normal aging

Indexed keywords

AMYLOID BETA PROTEIN; APOLIPOPROTEIN E; BIOLOGICAL MARKER; ISOPROSTANE; TAU PROTEIN;

ADULT; AGED; AGING; ALZHEIMER DISEASE; ARTICLE; BODY MASS; CEREBROSPINAL FLUID; GENOTYPE; HUMAN; HUMAN EXPERIMENT; NORMAL HUMAN; PRIORITY JOURNAL; RISK FACTOR;

ADULT; AGED; AGED, 80 AND OVER; AGING; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; APOLIPOPROTEIN E4; APOLIPOPROTEINS E; BIOLOGICAL MARKERS; DINOPROST; DNA MUTATIONAL ANALYSIS; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; OXIDATIVE STRESS; PEPTIDE FRAGMENTS; PHOSPHORYLATION; POLYMORPHISM, GENETIC; TAU PROTEINS;

EID: 62349135758     PISSN: 01974580     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2007.08.019     Document Type: Article

References (65)

1. Andreasen N., Vanmechelen E., Van d V., Davidsson P., Hesse C., Tarvonen S., Raiha I., Sourander L., Winblad B., and Blennow K. Cerebrospinal fluid tau protein as a biochemical marker for Alzheimer's disease: a community based follow up study. J. Neurol. Neurosurg. Psychiatry 64 (1998) 298-305
2. Arai H., Morikawa Y., Higuchi M., Matsui T., Clark C.M., Miura M., Machida N., Lee V.M., Trojanowski J.Q., and Sasaki H. Cerebrospinal fluid tau levels in neurodegenerative diseases with distinct tau-related pathology. Biochem. Biophys. Res. Commun. 236 (1997) 262-264
3. Augustinack J.C., Schneider A., Mandelkow E.M., and Hyman B.T. Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer's disease. Acta Neuropatholog. 103 1 (2002) 26-35
4. Bachman D.L., Wolf M.D., Linn R., Knoefel J.E., Cobb J., Belanger B.S., D'Agostino R.B., and White L.R. Incidence of dementia and probable Alzheimer's disease in a general population: the Framingham Study. Neurology 43 (1993) 515-519
5. Bennett D.A., Schneider J.A., Arvanitakis Z., Kelly J.F., Aggarwal N.T., Shah R.C., and Wilson R.S. Neuropathology of older persons without cognitive impairment from two community-based studies. Neurology 66 12 (2006) 1837-1844
6. Blennow K. CSF biomarkers for mild cognitive impairment. J. Int. Med. 256 (2004) 224-234
7. Blennow K., de Leon M.J., and Zetterberg H. Alzheimer's disease. Lancet Neurol. 368 (2006) 387-403
8. Blennow K., and Vanmechelen E. CSF markers for pathogenic processes in Alzheimer's disease: diagnostic implications and use in clinical neurochemistry. Brain Res. Bull. 61 (2003) 235-242
9. Blomberg M., Jensen M., Basun H., Lannfelt L., and Wahlund L.-O. Increasing cerebrospinal fluid tau levels in a subgroup of Alzheimer patients with apolipoprotien E allele e4 during 14 months follow-up. Neurosci. Lett. 214 2-3 (1996) 163-166
10. Blomberg M., Jensen M., Basun H., Lannfelt L., and Wahlund L.O. Cerebrospinal fluid tau levels increase with age in healthy individuals. Dement. Geriatr. Cogn. Disord. 12 (2001) 127-132
11. Briani C., Ruggero S., Naccarato M., Cagnin A., Ricchieri G.L., Pasqui L., Pizzolato G., and Battistin L. Combined analysis of CSF +|A42 peptide and tau protein and serum antibodies to glycosaminoglycans in Alzheimer's disease: preliminary data. J. Neural. Trans. V109 3 (2002) 393-398
12. Brys, M., Pirraglia, E., Rich, K., Rolstad, S., Mosconi, L., Switalski, R.,Glodzik-Sobanska, L., De Santi, S., Zinkowski, R., Metha, P.D., Pratico, D., Saint-Louis, L.A., Wallin, A., Blennow, K., de Leon, M.J., 2007. Prediction and longitudinal study of CSF biomarkers in mild cognitive impairment. Neurobiol. Aging, in press.
13. Buerger, K., Alafuzoff, I., Ewers, M., Pirttila, T., Zinkowski, R., Hampel, H., 2007. No correlation between CSF tau protein phosphorylated at threonine 181with neocortical neurofibrillary pathology in Alzheimer's disease. Brain, doi:10.1093/brain/awm140.
14. Buerger K., Ewers M., Pirttila T., Zinkowski R., Alafuzoff I., Teipel S.J., DeBernardis J., Kerkman D., McCulloch C., Soininen H., and Hampel H. CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease. Brain 129 (2006) 3035-3041
15. Buerger K., Zinkowski R., Teipel S.J., Tapiola T., Arai H., Blennow K., Andreasen N., Hofmann-Kiefer K., DeBernardis J., Kerkman D., McCulloch C., Kohnken R., Padberg F., Pirttila T., Schapiro M., Rapoport S., Moller H.J., Davies P., and Hampel H. Differential diagnosis of Alzheimer disease with cerebrospinal fluid levels of tau protein phosphorylated at threonine 231. Arch. Neurol. 59 8 (2002) 1267-1272
16. Burkhard P.R., Fournier R., Mermillod B., Krauze K.H., Bouras C., and Irminger I. Cerebrospinal fluid tau and Abeta42 concentrations in healthy subjects: delineation of reference intervals and their limitations. Clin. Chem. Lab. Med. 42 (2004) 396-407
17. Chen M., Inestrosa N.C., Ross G.S., and Fernandez H.L. Platelets Are the Primary Source of Amyloid [beta]-Peptide in Human Blood. Biochem. Biophys. Res. Commun. 213 1 (1995) 96-103
18. De Caterina R., Cipollone F., Filardo F.P., Zimarino M., Bernini W., Lazzerini G., Bucciarelli T., Falco A., Marchesani P., Muraro R., Mezzetti A., and Ciabattoni G. Low-density lipoprotein level reduction by the 3-hydroxy-3-methylglutaryl coenzyme-a inhibitor simvastatin is accompanied by a related reduction of f2-isoprostane formation in hypercholesterolemic subjects: no further effect of vitamin E. Circulation 106 20 (2002) 2543-2549
19. de Leon M.J., Convit A., Wolf O.T., Tarshish C.Y., De Santi S., Rusinek H., Tsui W., Kandil E., Scherer A.J., Roche A., Imossi A., Thorn E., Bobinski M., Caraos C., Lesbre P., Schlyer D., Poirier J., Reisberg B., and Fowler J. Prediction of cognitive decline in normal elderly subjects with 2-[18F]fluoro-2-deoxy-d-glucose/positron-emission tomography (FDG/PET). Proc. Natl. Acad. Sci. USA 98 19 (2001) 10966-10971
20. de Leon, M.J., Mosconi, L., Li, Y., De Santi, S., Yao, Y., Tsui, W.H., Pirraglia, E., Rich, K.E., Javier, E., Brys, M., Glodzik-Sobanska, L., Switalski, R., Saint, L.L., Pratico, D., 2007. Longitudinal CSF isoprostane and MRI measures in the progression to AD. J. Neurol., in press.
21. Dietrich M., Hu Y., Block G., Olano E., Packer R., Morrow J.D., Hudes M., Abdukeyum G., Rimbach G., and Minihana M.A. Associations between apolipoprotein E genotype and circulating F2-isoprostane levels in humans. Lipids 40 (2005) 329-334
22. Engelborghs S., Sleegers K., Cras P., Brouwers N., Serneels S., De L.E., Martin J.J., Vanmechelen E., Van B.C., and De Deyn P.P. No association of CSF biomarkers with APOE{varepsilon}4, plaque and tangle burden in definite Alzheimer's disease. Brain 130 9 (2007) 2320-2326
23. Fagan A.M., Roe C.M., Xiong C., Mintun M., Morris J.C., and Holtzman DM. Cerebrospinal Fluid tau/beta-Amyloid42 Ratio as a Prediction of Cognitive Decline in Nondemented Older Adults. Arch. Neurol. (2007) 10.1001/archneur.64.3.noc60123
24. Fagan A.M., Younkin L.H., Morris J.C., Fryer J.D., Cole T.G., Younkin S.G., and Holtzman D.M. Differences in the Abeta40/Abeta42 ratio associated with cerebrospinal fluid lipoproteins as a function of apolipoprotein E genotype. Ann. Neurol. 48 2 (2000) 201-210
25. Farrer L.A., Cuples L.A., Haines J.L., Hyman B., Kukull W.A., Mayeux R., Myers R.H., Pericak-Vance M.A., Rish N., and Dujin C.M. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer Disease. JAMA 278 16 (1997) 1349-1356
26. Galasko D., Chang L., Motter R., Clark C.M., Kaye J., Knopman D., Thomas R., Kholodenko D., Schenk D., Lieberburg I., Miller B., Green R., Basherad R., Kertiles L., Boss M.A., and Seubert P. High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype. Arch. Neurol. 55 7 (1998) 937-945
27. Gilbert J.G., Levee R.F., and Catalano F.L. A preliminary report on a new memory scale. Percept. Mot. Skills 27 (1968) 277-278
28. Glodzik-Sobanska L., Rusinek H., Mosconi L., Li Y., Zhan J., De Santi S., Convit A., Rich K.E., Brys M., and de Leon M.J. The role of quantitative structural imaging in the early diagnosis of Alzheimer's disease. Neuroimaging Clin. N. Am. 15 (2005) 803-826
29. Golombowski S., Muller-Spahn F., Romig H., Mendla K., and Hock C. Dependence of cerebrospinal fluid Tau protein levels on apolipoprotein E4 allele frequency in patients with Alzheimer's disease. Neurosci. Lett. 225 (1997) 213-215
30. Greenow K., Pearce N.J., and Ramji D.P. The key role of apolipoprotein E in atherosclerosis. J. Mol. Med. 83 (2005) 329-342
31. Hampel H., Buerger K., Zinkowski R., Teipel S.J., Goernitz A., Andreasen N., Sjoegren M., DeBernardis J., Kerkman D., Ishiguro K., Ohno H., Vanmechelen E., Vanderstichele H., McCulloch C., Moller H.J., Davies P., and Blennow K. Measurement of Phosphorylated tau epitopes in the differential diagnosis of alzheimer disease: a comparative cerebrospinal fluid study. Arch. Gen. Psychiatry 61 1 (2004) 95-102
32. Hansson O., Zetterberg H., Buchhave P., Londos E., Blennow K., and Minthon L. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol. 5 3 (2006) 228-234
33. Itoh N., Arai H., Urakami H., Ishiguro K., Ohno H., Hampel H., Buerger K., Wiltfang J., Otto M., Kretzschmar H.A., Moeller H.J., Imagawa M., Kohno H., Nakashima K., Kuzuhara S., Sasaski H., and Imahori H. Large-scale, multicenter study of cerebrospinal fluid tau protein phosphorylated at serine 199 for the antemortem diagnosis of Alzheimer's disease. Ann. Neurol. 50 (2001) 150-156
34. Jensen M., Basun H., and Lannfelt L. Increased cerebrospinal fluid tau in patients with Alzheimer's disease. Neurosci. Lett. 186 (1995) 189-191
35. Khachaturian A.S., Corcoran C.D., Mayer L.S., Zandi P.P., and Breitner J.C.S. Apolipoprotein E {epsilon}4 Count Affects Age at Onset of Alzheimer Disease, but Not Lifetime Susceptibility: The Cache County Study. Arch. Gen. Psychiatry 61 5 (2004) 518-524
36. Knopman D.S., Parisi J.E., Salviati A., Floriach-Robert M., Boeve B.F., Ivnik R.J., Smith G.E., Dickson D.W., Johnson K.A., Petersen L.E., McDonald W., Braak H., and Petersen R.C. Neuropathology of cognitively normal elderly. J. Neuropathol. Exp. Neurol. 62 11 (2003) 1087-1095
37. Kohnken R., Buerger K., Zinkowski R., Miller C., Kerkman D., DeBernardis J., Shen J., Moller H.J., Davies P., and Hampel H. Detection of tau phosphorylated at threonine 231 in cerebrospinal fluid of Alzheimer's disease patients. Neurosci. Lett. (2000) 187-190
38. Lewczuk P., Esselmann H., Bibl M., Beck G., Maler J.M., Otto M., Kornhuber J., and Wiltfang J. Tau protein phosphorylated at threonine 181 in csf as a neurochemical biomarker in Alzheimer's disease. J. Mol. Neurosci. 23 (2004) 115-122
39. Lewczuk P., Esselmann H., Otto M., Maler J.M., Henkel A.W., Henkel M.K., Eikenberg O., Antz C., Krause W.R., Reulbach U., Kornhuber J., and Wiltfang J. Neurochemical diagnosis of Alzheimer's dementia by CSF A[beta]42 A[beta]42/A[beta]40 ratio and total tau. Neurobiol. Aging 25 3 (2004) 273-281
40. Mahley R.W., Weisgraber K.H., and Huang J. Apolipoprotein E4: a causative factor and therapeutic target in neuropathology, including Alzheimer's disease. PNAS 103 (2006) 5644-5651
41. Main B.F., Jones P.J., MacGillivray R.T., and Banfield D.K. Apolipoprotein E genotyping using the polymerase chain reaction and allele-specific oligonucleotide primers. J. Lipid Res. 32 (1991) 183-187
42. Metha P.D., Pirttila T., Metha S.P., Sersen E., Aisen P.S., and Wisnewski H.M. Plasma and cerebrospinal fluids levels of amyloid beta proteins 1-40 and 1-42 in Alzheimer's disease. Arch. Neurol. 57 (2000) 100-105
43. Mitchell A., and Brindle N. CSF phosphorylated tau-does it constitute an accurate biological test for Alzheimer's disease?. Int. J. Geriatr. Psychiatry 18 5 (2003) 407-411
44. Mollenhauer B., Bibl M., Trenkwalder C., Stiens G., Cepek L., Steinacker P., Ciesielczyk B., Neubert K., Wiltfang J., Kretzschmar H.A., Poser S., and Otto M. Follow-up investigations in cerebrospinal fluid of patients with dementia with Lewy bodies and Alzheimers disease. J. Neural. Trans. 112 7 (2005) 933-948
45. Mori H., Hosoda K., Matsubara E., Nakamoto T., Furiya Y., Endoh R., Usami M., Shoji M., Maruyama S., and Hirai S. Tau in cerebrospinal fluids: establishment of the sandwich ELISA with antibody specific to the repeat sequence in tau. Neurosci. Lett. 186 2-3 (1995) 181-183
46. Mosconi L, Reiman EM, Tsui WH, Chen K, De Santi S, Li Y, Caselli RJ, Alexander G, de Leon MJ. Reduced brain glucose metabolism predicts cognitive decline in normal ApoE E4 carriers. in prep 2007.
47. Ohm T.G., Scharnagl H., Marz W., and Bohl J. Apolipoprotein E isoforms and the development of low and high Braak stages of Alzheimer's disease-related lesions. Acta Neuropathol. 98 (1999) 273-280
48. Peskind E.R., Li G., Shofer J., Quinn J.F., Kaye J.A., Clark C.M., Farlow M.R., DeCarli C., Raskind M.A., Schellenberg G.D., Lee V.M.Y., and Galasko D.R. Age and apolipoprotein E*4 allele effects on cerebrospinal fluid beta-amyloid 42 in adults with normal. Cogn. Arch. Neurol. 63 7 (2006) 936-939
49. Pratico D., Clark C.M., Lee V.M., Trojanowski J.Q., Rokach J., and Fitzgerald G.A. Increased 8.12-iso-iPF2alpha-VI in Alzheimer's disease: correlation of a noninvasive index of lipid peroxidation with disease severity. Ann. Neurol. 48 5 (2000) 809-812
50. Pratico D., Clark C.M., Liun F., Lee V.Y., and Trojanowski J.Q. Increase of brain oxidative stress in mild cognitive impairment: a possible predictor of Alzheimer disease. Arch. Neurol. 59 6 (2002) 972-976
51. Ramassamy C., Averill D., Beffert U., Theroux L., Lussier-Cacan S., Cohn J.S., Christen Y., Schoofs A., Davignon J., and Poirier J. Oxidative Insults are associated with apolipoprotein E genotype in alzheimer's disease brain. Neurobiol. Dis. 7 1 (2000) 23-37
52. Reiman E.M., Caselli R.J., Yun L.S., Chen K., Bandy D., Minoshima S., Thibodeau S.N., and Osborne D. Preclinical evidence of Alzheimer's disease in persons homozygous for the E4 allele for apolipoprotein E. N. Engl. J. Med. 334 12 (1996) 752-758
53. Reisberg B., London E., Ferris S.H., Borenstein J., Scheier L., and de Leon M.J. The Brief Cognitive Rating Scale: Language, motoric, and mood concomitants in primary degenerative dementia. Psychopharmacol. Bull. 19 (1983) 702-708
54. Reisberg B., Sclan S.G., Franssen E.H., de Leon M.J., Kluger A., Torossian C.L., Shulman E., Steinberg G., Monteiro I., McRae T., Boksay I., Mackell J.A., and Ferris S.H. Clinical stages of normal aging and Alzheimer's disease: the GDS staging system. Neurosci. Res. Commun. 13 Suppl. 1 (1993) 551-554
55. Rusinek H., De Santi S., Frid D., Tsui W., Tarshish C., Convit A., and de Leon M.J. Regional brain atrophy rate predicts future cognitive decline: 6-year longitudinal MR imaging study of normal aging. Radiology 229 (2003) 691-696
56. Shoji M., Matsubara E., Kanai M., Watanabe M., Nakamura T., Tomidokoro Y., Shizuka M., Wakabayashi K., Igeta Y., Ikeda Y., Mizushima K., Amari M., Ishiguro K., Kawarabayashi T., Harigaya Y., Okamoto K., and Hirai S. Combination assay of CSF Tau, Aβ1-40 and Aβ1-42(43) as a biochemical marker of Alzheimer's disease. J. Neurol. Sci. 158 2 (1998) 134-140
57. Sjogren M., Vanderstichele H., Agren H., Zachrisson O., Edsbagge M., Wikkelso C., Skoog I., Wallin A., Wahlund L.O., Marcusson J., Nagga K., Andreasen N., Davidsson P., Vanmecheln E., and Blennow K. Tau and Abeta42 in cerebrospinal fluid from healthy adults 21-93 years of age: establishment of reference values. Clin. Chem. 47 10 (2001) 1776-1781
58. Sultana R., Perluigi M., and Butterfield D.A. Protein Oxidation and lipid peroxidation in brain of subjects with Alzheimer's disease: Insights into Mechanism of neurodegeneration from redox proteomics. Antioxid. Redox Signal. 8 11-12 (2006) 2021-2037
59. Sunderland T., Mirza N., Putnam K.T., Linker G., Bhupali D., Durham R., Soeares H., Kimmel L., Friedman D., Bergerson J., Casko G., Levy J.A., Bartko J.J., and Cohen R.M. Cerebrospinal fluid beta-amyloid1-42 and tau in control subjects at risk for Alzheimer's disease: the effect of APOE epsilon4 allele. Biol. Psychiatry 56 (2004) 670-676
60. Sutherland W.H.F., Manning P.J., Walker R.J., de Jong S.A., Ryalls A.R., and Berry E.A. Vitamin E Supplementation and Plasma 8-Isoprostane and Adiponectin in Overweight Subjects. Obesity 15 2 (2007) 386-391
61. Uylings H.B.M., and de Brabander J.M. Neuronal Changes in Normal Human Aging and Alzheimer's disease. Brain Cogn. 49 (2002) 268-276
62. Wechsler D. WAIS-R Manual (1981), Psychological Corporation, New York
63. Wiltfang J., Esselmann H., Bibl M., Hull M., Hampel H., Kessler H., Frolich L., Schroder J., Peters O., Jessen F., Luckhaus C., Perneczky R., Jahn H., Fiszer M., Maler J.M., Zimmermann R., Bruckmoser R., Kornhuber J., and Lewczuk P. Amyloid beta peptide ratio 42/40 but not Abeta42 correlates with phospho-Tau in patients with low- and high-CSF Abeta40 load. J. Neurochem. 101 4 (2007) 1053-1059
64. Xhignesse M., Lussier-Cacan S., Sing C.F., Kessling A.M., and Davignon J. Influences of common variants of apolipoprotein E on measures of lipid metabolism in a sample selected for health. Arterioscler. Thromb. 11 (1991) 1100-1110
65. Zhu X., Raina A.K., Lee H.G., Chao M., Nunomura A., Tabaton M., Petersen R.B., Perry G., and Smith M.A. Oxidative stress and neuronal adaptation in Alzheimer disease: the role of SAPK pathways. Antioxid. Redox Signal. 5 (2003) 571-576